clofarabine has been researched along with Abnormalities, Autosome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Thomas, DA; Verstovsek, S | 1 |
| Beran, M; Cortes, J; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Koller, C; Kwari, M; O'Brien, S; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
2 trial(s) available for clofarabine and Abnormalities, Autosome
| Article | Year |
|---|---|
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Survival Rate | 2008 |
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Topics: Acute Disease; Adenine Nucleotides; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome | 2006 |